Lifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic Melanoma
Amod A Sarnaik,Omid Hamid,Nikhil I Khushalani,Karl D Lewis,Theresa Medina,Harriet M Kluger,Sajeve S Thomas,Evidio Domingo-Musibay,Anna C Pavlick,Eric D Whitman,Salvador Martin-Algarra,Pippa Corrie,Brendan D Curti,Judit Oláh,Jose Lutzky,Jeffrey S Weber,James M G Larkin,Wen Shi,Toshimi Takamura,Madan Jagasia,Harry Qin,Xiao Wu,Cecile Chartier,Friedrich Graf Finckenstein,Maria Fardis,John M Kirkwood,Jason A Chesney
DOI: https://doi.org/10.1200/JCO.21.00612
2021-08-20
Abstract:Purpose: Effective treatment options are limited for patients with advanced (metastatic or unresectable) melanoma who progress after immune checkpoint inhibitors and targeted therapies. Adoptive cell therapy using tumor-infiltrating lymphocytes has demonstrated efficacy in advanced melanoma. Lifileucel is an autologous, centrally manufactured tumor-infiltrating lymphocyte product. Methods: We conducted a phase II open-label, single-arm, multicenter study in patients with advanced melanoma who had been previously treated with checkpoint inhibitor(s) and BRAF ± MEK targeted agents. Lifileucel was produced from harvested tumor specimens in central Good Manufacturing Practice facilities using a streamlined 22-day process. Patients received a nonmyeloablative lymphodepletion regimen, a single infusion of lifileucel, and up to six doses of high-dose interleukin-2. The primary end point was investigator-assessed objective response rate (ORR) per RECIST, version 1.1. Results: Sixty-six patients received a mean of 3.3 prior therapies (anti-programmed death 1 [PD-1] or programmed death ligand 1 [PD-L1]: 100%; anticytotoxic T-lymphocyte-associated protein-4: 80%; BRAF ± MEK inhibitor: 23%). The ORR was 36% (95% CI, 25 to 49), with two complete responses and 22 partial responses. Disease control rate was 80% (95% CI, 69 to 89). Median duration of response was not reached after 18.7-month median study follow-up (range, 0.2-34.1 months). In the primary refractory to anti-PD-1 or PD-L1 therapy subset, the ORR and disease control rate were 41% (95% CI, 26 to 57) and 81% (95% CI, 66 to 91), respectively. Safety profile was consistent with known adverse events associated with nonmyeloablative lymphodepletion and interleukin-2. Conclusion: Lifileucel demonstrated durable responses and addresses a major unmet need in patients with metastatic melanoma with limited treatment options after approved therapy, including the primary refractory to anti-PD-1 or PD-L1 therapy subset.